1[15]Parfitt K. Martindale the Complete Drug Reference [ M]. 32nd ed. London: Pharmaceutical Press, 1999: 381.
2[16]Thomas W, Peter P, Drew WJ, et al. Vioriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever[J]. Eng J Med, 2002,346(4): 225.
3[18]Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent[J]. Clin InfDis ,2003,36(5) :630.
4[19]Ryder NS, Leitner I. Synergistic interaction of terbinafine with triazoles or amphotericin B agoinst aspergillus species[J]. Med Mycol,2001,39( 1 ) :91.
5[20]Ryder NS. Activity of terbinafine against serious fungal pathogens[J]. Mycoses, 1999,42( Suppl 2): S115.
6[21]Ghannoum MA, Elewski B. Successful treatment of fluconazole resistant oropharyngeal candidiasis by a combination of fluconazole and terbinafine[ J]. Clin Diagn Lab Immunol, 1999,6(6):921.
7[1]Loeffler J, Stevens DA. Antifungal drug resisitance [ J ]. Clin Int Dis, 2003,36 ( Suppl 1 ): S31.
8[3]Garbino J, Lew D, Hirschel B, et al. Caspofungin in the treat ment of oropharyngeal candidiasis [ J ]. Int J Clin Pract, 2003,57(2): 143.
9[4]Li RK, Rinaldi MG. In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole [ J ]. Antimicrob Agents Chemother ,1999 ,43( 6 ) :1 401.
10[5]Plaller MA, Diekema DJ, Messer SA. In vitro activities of voriconazole, posaconazole and four licensed systemic antifungal agents against canadida species infrequently isolatied from blood[ J ]. J Clin Microbiol, 2003,41 ( 1 ): 78.
